Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Axsome Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Axsome Therapeutics şirketinin toplam hissedar öz sermayesi $102.9M ve toplam borcu $179.3M olup, bu da borç-öz sermaye oranını 174.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $548.2M ve $445.4M dir.
Anahtar bilgiler
174.4%
Borç/özkaynak oranı
US$179.33m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$315.66m |
| Eşitlik | US$102.85m |
| Toplam yükümlülükler | US$445.37m |
| Toplam varlıklar | US$548.23m |
Son finansal sağlık güncellemeleri
Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Recent updates
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Sep 06Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: AXSM 'nin kısa vadeli varlıkları ( $463.0M ) kısa vadeli yükümlülüklerini ( $186.6M ) aşıyor.
Uzun Vadeli Yükümlülükler: AXSM şirketinin kısa vadeli varlıkları ( $463.0M ) uzun vadeli yükümlülüklerini ( $258.8M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: AXSM şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: AXSM şirketinin borç/öz sermaye oranı son 5 yılda 80.6% seviyesinden 174.4% seviyesine yükseldi.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: AXSM şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.
Tahmini Nakit Akışı: AXSM tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.